Unlike the 22C3, 28-8, and SP263 antibodies, which assess PD-L1 expression only on tumor cell membranes, the SP142 antibody assay used for atezolizumab measures PD-L1 levels in both TCs and ICs. The gene discussed is CD274; the disease is neoplasm.